icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks
 
 
  Reported by Jules Levin
AASLD 2016 Nov 13-17 San Francisco
 
Jacobson IM1; Asante-Appiah E2; Wong P2; Black T2; Howe A2; Wahl J2; Robertson MN2; Nguyen B-Y2;
Shaughnessy M2; Hwang P2; Barr E2; Hazuda D2
1Mount Sinai Beth Israel, New York, NY, USA; 2Merck & Co., Inc., Kenilworth, NJ, USA

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif

AASLD15.gif

AASLD16.gif

AASLD17.gif